• In August 2026, Royalty Pharma plc agreed to provide US$100 million in funding to Zealand Pharma A/S in return for Zealand’s economic interests in rusfertide (PTG-300), including a 1% royalty on potential future global net sales and associated milestone payments, with payments split between closing and the first anniversary.
• This deal gives Royalty Pharma exposure to a potential first-in-class therapy for polycythemia vera while leaving Zealand Pharma with a smaller upside royalty on very high future sales, highlighting how royalty structures can share risk and reward between capital providers and drug developers.
• We’ll now examine how Royalty Pharma’s US$100 million rusfertide royalty acquisition shapes its broader investment narrative and future cash-flow profile.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Royalty Pharma Investment Narrative Recap

To own Royalty Pharma, you need to believe in its ability to keep recycling cash into attractive biopharma royalties while managing concentration and policy risks. The US$100 million rusfertide deal adds another rare disease exposure, but it is not large enough on its own to change the near term focus on the Alyftrek royalty dispute and competitive pressure in royalty financing. Its impact on the most important short term catalysts and biggest risks looks modest for now.

The recent second quarter 2026 results are the most relevant backdrop for this deal. Revenue grew to US$674.14 million from US$578.67 million a year earlier, while quarterly net income softened to US$17.88 million. Against that context, committing US$100 million to rusfertide extends Royalty Pharma’s pipeline of potential future cash flows, but also underlines how new deals must keep offsetting product specific headwinds and any regulatory or pricing pressure on existing royalty streams.

Yet even as the rusfertide deal broadens the portfolio, the unresolved Alyftrek royalty dispute still leaves investors exposed to...

Royalty Pharma's narrative projects $4.3 billion revenue and $3.2 billion earnings by 2029. This requires 20.9% yearly revenue growth and about a $2.4 billion earnings increase from $826.3 million today.

Uncover how Royalty Pharma's forecasts yield a $59.25 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming earnings might need to reach about US$3.2 billion by 2029, while still warning that regulatory pressure on drug pricing could undercut those royalty streams; the rusfertide deal could either help offset that concern or prove too small to matter, which is why it is worth comparing how differently you and those pessimists may see the same numbers.

Explore 5 other fair value estimates on Royalty Pharma - why the stock might be worth just $58.00!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Royalty Pharma research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Royalty Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Royalty Pharma's overall financial health at a glance.

Seeking Other Investments?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find 50 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.